Ischemic cardiomyopathy

InvestmentPitch Media Video Discusses Hemostemix and its Hiring of 4 Biotechnologists to Re-Establish Production of ACP-01 in Montreal and Applying for Grants to Fund Up to 75% of 5-Year Expenses

Retrieved on: 
Tuesday, January 24, 2023
Quality control, McGill University Health Centre, Ischemia, Cardiomyopathy, Bone marrow, CGMP, B cell, Commitment, HEM, Federal, Letter, Ischemic cardiomyopathy, Clinical trial, News, Pharmaceutical industry

The video is available for viewing on “ InvestmentPitch ” and on “ YouTube ”.

Key Points: 
  • The video is available for viewing on “ InvestmentPitch ” and on “ YouTube ”.
  • If these links are not enabled, please visit www.InvestmentPitch.com and enter “Hemostemix” in the search box.
  • The company is hiring an experienced stem cell therapy Manufacturing Manager, a Quality Control Manager, and two Manufacturing Technologists.
  • For more information, please visit the company’s website at www.hemostemix.com , contact Thomas Smeenk, President, CEO and Co-Founder at 905-580-4170 or by email at [email protected] .

InvestmentPitch Media Video Discusses Hemostemix and its $250,000 in Funding from McGill University Health Centre Foundation for Clinical Trial of ACP-01

Retrieved on: 
Monday, January 23, 2023
Disease, MUHC, Department of Mechanical Engineering, Imperial College London, Systematic review, McGill University, Principal, McGill University Health Centre, Beckman Research Institute, Ischemia, Cardiomyopathy, Blood, Bone marrow, B cell, Commitment, HEM, Research, Mechanical engineering, Myocardial infarction, Cardiology, Heart failure, Dream, Letter, Patient, Ischemic cardiomyopathy, Partnership, Clinical trial, Surgery, Research institute, Meta-analysis, Regeneration, Medicine, MI, Associate, Stanford University, McGill, Department of Medicine – University of Pamplona, News, Pharmaceutical industry

If these links are not enabled, please visit www.InvestmentPitch.com and enter “Hemostemix” in the search box.

Key Points: 
  • If these links are not enabled, please visit www.InvestmentPitch.com and enter “Hemostemix” in the search box.
  • In 2020, the MUHC Foundation launched its $200 million Dream Big Campaign to change the course of lives and medicine.
  • To reach that goal, Hemostemix and the MUHC Foundation are committed to working together with federal and provincial partners alongside donors to fund the phase II clinical trial at the McGill University Health Centre.
  • The MUHC Foundation is proud to help bring this ground-breaking clinical trial to the MUHC.

BioCardia Receives No Objection Letter from Health Canada, Enabling Company to Expand CardiAMP Cell Therapy Heart Failure Trial into Canada

Retrieved on: 
Tuesday, March 1, 2022
GLOBE, Therapy, Cell, Probability, NYHA, Overalls, III, Security (finance), Phase, Letter, Bone marrow, NK1R, New York Heart Association Functional Classification, Company, Clinical trial, Heart, Cell therapy, Heart failure, U.S. Securities and Exchange Commission, Ischemic cardiomyopathy, Health Canada, Forward-looking statement, Patient, Quality of life, Survival, Pharmaceutical industry

The CardiAMP Cell Therapy Heart Failure Trial is evaluating the effectiveness of the CardiAMP Cell Therapy System for improving survival, reducing major adverse cardiac events, enhancing functional capacity, and improving quality of life for New York Heart Association (NYHA) Class II and III patients who have heart failure associated with ischemic cardiomyopathy.

Key Points: 
  • The CardiAMP Cell Therapy Heart Failure Trial is evaluating the effectiveness of the CardiAMP Cell Therapy System for improving survival, reducing major adverse cardiac events, enhancing functional capacity, and improving quality of life for New York Heart Association (NYHA) Class II and III patients who have heart failure associated with ischemic cardiomyopathy.
  • Expansion into respected centers in Canada is expected to strengthen the overall clinical trial and accelerate its completion, saidPeter Altman, Ph.D., President and Chief Executive Officer of BioCardia.
  • The Health Canada process has been longer than expected as the trial was required to be approved by both the devices and the biologics groups at Health Canada in a sequential process.
  • The CardiAMP Cell Therapy Heart Failure Trial is the first multicenter clinical trial of a stem cell therapy to prospectively screen for stem cell therapeutic potency in order to improve patient outcomes.

Olatec Announces High-Impact Coverage of Dapansutrile in Leading Journal on Cardiovascular Disease as well as Another Publication from New Preclinical Data in a Heart Failure Model

Retrieved on: 
Tuesday, February 15, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, Protein, Infarction, Prevalence, HF, NLRP3, Cardiology, Therapy, JACC, Inflammation, Model, LLC, SCI, Journal of Cardiovascular Pharmacology and Therapeutics, Company, Journal, Manuscript, Pharmacology, Virginia Commonwealth University, Compliance, Melanoma, Degenerative disease, Associate, Genetics, Industry, Cardiovascular disease, Oslo University Hospital, Review, American College, Infection, Heart failure, Myocardial infarction, Inflammasome, Mouse, Principal, Arthritis, Multiple sclerosis, Medical director, CVD, OLT, Asthma, Patient, Synthetic control method, Ischemic cardiomyopathy, Molecule, IP, Canakinumab, Press release, Ageing, Institute for Health Metrics and Evaluation, AMI, Reperfusion, Pharmaceutical industry, Medicine, Heart Failure, Dapansutrile, Olatec Therapeutics LLC, HEART FAILURE, DAPANSUTRILE, OLATEC THERAPEUTICS LLC

Changes to heart architecture through age, genetics, and/or lifestyle factors gradually weaken the hearts mechanical function and add stress to cardiac tissue.

Key Points: 
  • Changes to heart architecture through age, genetics, and/or lifestyle factors gradually weaken the hearts mechanical function and add stress to cardiac tissue.
  • Activation and upregulation of IL-1-dependent inflammation drives additional structural changes that further compromise heart function and contribute to the development and exacerbation of CVD.
  • Olatec is also pleased to report on another publication in CVD, covering dapansutriles new preclinical data demonstrating its cardio protective effects in this model.
  • Data in mice show significant preservation of contractile reserve and diastolic function in an experimental model of heart failure due to severe ischemic cardiomyopathy.

Yashoda Hospitals, Hyderabad, India gives a new lease of life to 31 Year-old Footballer from Uganda through L-VAD (Left Ventricular Assist Device)

Retrieved on: 
Friday, February 11, 2022
LVAD, Patient, Ear, Bed, Interdisciplinarity, Abdominal distension, Ischemic cardiomyopathy, Group, Heart, Travel, Coronary artery disease, Hospital, Yashoda Hospitals, Medicine, Chest pain, Lung, Medical imaging, Cardiology

He had developed chest pain while playing football in April '21 at Uganda.

Key Points: 
  • He had developed chest pain while playing football in April '21 at Uganda.
  • The latest and most advanced modality of treatment (JARVIK 2000 SERIES) was offered at Yashoda Hospitals with state-of-the-art facilities, latest and advanced equipment.
  • Mr. Okwara Joseph was successfully operated on 24thDecember 2021, got a new lease of life and was discharged on 28thJanuary 2022 from Yashoda Hospitals, Hyderabad, India.
  • The Group has been providing quality healthcare for 3 decades in virtually every specialty and subspecialty of medicine and surgery.

Yashoda Hospitals, Hyderabad, India gives a new lease of life to 31 Year-old Footballer from Uganda through L-VAD (Left Ventricular Assist Device)

Retrieved on: 
Friday, February 11, 2022
LVAD, Patient, Ear, Bed, Interdisciplinarity, Abdominal distension, Ischemic cardiomyopathy, Group, Heart, Travel, Coronary artery disease, Hospital, Yashoda Hospitals, Medicine, Chest pain, Lung, Medical imaging, Cardiology

He had developed chest pain while playing football in April '21 at Uganda.

Key Points: 
  • He had developed chest pain while playing football in April '21 at Uganda.
  • The latest and most advanced modality of treatment (JARVIK 2000 SERIES) was offered at Yashoda Hospitals with state-of-the-art facilities, latest and advanced equipment.
  • Mr. Okwara Joseph was successfully operated on 24thDecember 2021, got a new lease of life and was discharged on 28thJanuary 2022 from Yashoda Hospitals, Hyderabad, India.
  • The Group has been providing quality healthcare for 3 decades in virtually every specialty and subspecialty of medicine and surgery.

First-in-Human Use of Investigational NRP-DCD Method Using Paragonix SherpaPak by University of Nebraska Medical Center

Retrieved on: 
Wednesday, December 1, 2021
Other Transport, Medical Devices, Surgery, Hospitals, Transport, Cardiology, University, Health, Logistics, Supply Chain Management, Education, LinkedIn, Jean-Louis Vincent, Patient, Heart, University of Nebraska Medical Center, CEO, Safety, IRB, CE, NIH, Transport, NCT, Assistant professor, Doctor of Philosophy, University, Nebraska Medicine, Institutional review board, NRP, Male, National, ClinicalTrials.gov, Dan Jawitz, DCD, Research, Nebraska, FDA, Ischemic cardiomyopathy, Division, Heart transplantation, Travel, CTS, Medical device

Paragonix Technologies , the leading hypothermic donor organ preservation provider, announced the first-in-human clinical use of the investigational NRP-DCD Method by the University of Nebraska Medical Center to recover a donor heart and transport it utilizing the Paragonix SherpaPak System.

Key Points: 
  • Paragonix Technologies , the leading hypothermic donor organ preservation provider, announced the first-in-human clinical use of the investigational NRP-DCD Method by the University of Nebraska Medical Center to recover a donor heart and transport it utilizing the Paragonix SherpaPak System.
  • The University of Nebraska Medical Center and its clinical partner, Nebraska Medicine, recently cited as one of the Top 10 most trusted health system brands , is conducting a NRP-DCD study with oversight from their Institutional Review Board (IRB).
  • said Dr. Marian Urban, Assistant Professor, Division of Cardiac Surgery, University of Nebraska Medical Center.
  • For important safety information on the Paragonix SherpaPak System please visit: Important Safety Information
    Connect with us on LinkedIn: Paragonix Technologies
    1.

Hemostemix Announces the First of a Series of 2021 Video Interviews with ACP-01 Recipients: What the Successful Compassionate Treatment of Ischemic Cardiomyopathy Looks Like After 13 Years

Retrieved on: 
Tuesday, September 14, 2021
Risk, Patient, Quality of life, TSX Venture Exchange, SEDAR, Failure, Depression, Ischemic cardiomyopathy, Company, Patent, Amputation, Dilated cardiomyopathy, Intention, Clinical trial, Chronic obstructive pulmonary disease, Indian stock exchange, Ischemia, Transmyocardial revascularization, Safety, PAD, Legislation, Vascular dementia, COVID-19, HEM, OTC, Demand, Ulcer, Stem cell, Apple Inc. litigation, Research, CLI, News, Lawsuit, Pharmaceutical industry

Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003.

Key Points: 
  • Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003.
  • A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia.
  • Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation.
  • This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable.

Maintaining Heart Function After a Heart Attack

Retrieved on: 
Thursday, March 4, 2021
Aging-associated diseases, Branches of biology, Anatomy, Circulatory system, Acute pain, Medical emergencies, Myocardial infarction, Ischemia, Heart failure, Infarction, Ischemic cardiomyopathy

Heart attack not only causes instant chest pain and discomfort but also leads to a long-term ischemic injury to the heart that can result in a heart failure.In the process of myocardial ischemic infarction, an essential trace element copper is pushed out from the heart.

Key Points: 
  • Heart attack not only causes instant chest pain and discomfort but also leads to a long-term ischemic injury to the heart that can result in a heart failure.In the process of myocardial ischemic infarction, an essential trace element copper is pushed out from the heart.
  • Previous studies have demonstrated that repletion of copper to the copper-deficient ischemic heart can repair the damaged heart and facilitate recovery of heart function.
  • Genetic deletion of the COMMD1 gene in the heart blocked copper loss from the heart after ischemic insult.
  • Importantly, prevention of copper loss from the heart remarkably suppressed heart tissue death and preserved heart function.Dr.

Okayama University research: Skipping a beat -- a novel method to study heart attacks

Retrieved on: 
Thursday, November 12, 2020
Aging-associated diseases, Circulatory system, Cardiovascular system, Cardiovascular diseases, Acute pain, Myocardial infarction, Coronary artery disease, Heart, Cardiovascular disease, Ischemic cardiomyopathy

Ischemic heart disease often leads to heart attacks and is the leading cause of death worldwide.

Key Points: 
  • Ischemic heart disease often leads to heart attacks and is the leading cause of death worldwide.
  • Scientists rely on animal models such as rats and mice to study ischemic heart disease.
  • The video can be accessed at: https://www.jove.com/t/61104/model-ischemic-heart-disease-video-based-co...
    Ischemic heart disease Ischemic heart disease is a fatal condition that stems from an inadequate blood supply to the heart muscles.
  • Ischemic heart disease is the leading cause of mortality worldwide, and accounts for 40% of heart diseaserelated deaths in Japan.